NuGen Medical Devices Inc.
NGMD.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -93.54% | 46.79% | 131.25% | 139.52% | 351.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -93.54% | 46.79% | 131.25% | 139.52% | 351.80% |
| Cost of Revenue | -95.06% | 52.38% | 133.33% | 73.41% | 525.24% |
| Gross Profit | -92.02% | 43.28% | 130.77% | 254.75% | 250.46% |
| SG&A Expenses | -46.23% | 59.54% | -47.56% | -56.85% | 10.56% |
| Depreciation & Amortization | -- | 1.37% | -14.08% | 0.71% | -14.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.32% | 45.93% | -41.30% | -47.25% | 18.44% |
| Operating Income | 44.53% | -45.91% | 46.83% | 61.60% | -0.04% |
| Income Before Tax | 37.15% | -141.63% | 180.73% | 119.31% | -27.04% |
| Income Tax Expenses | -141.77% | -- | -- | -114.97% | 1,480.00% |
| Earnings from Continuing Operations | 37.52% | -142.06% | 180.53% | 119.26% | -27.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.52% | -142.06% | 180.53% | 119.26% | -27.46% |
| EBIT | 44.53% | -45.91% | 46.83% | 61.60% | -0.04% |
| EBITDA | 48.67% | -59.83% | 51.84% | 67.50% | -1.38% |
| EPS Basic | 40.00% | -131.25% | 172.73% | 117.89% | -8.70% |
| Normalized Basic EPS | 40.32% | -119.05% | 173.17% | 76.27% | -3.33% |
| EPS Diluted | 40.00% | -131.25% | 172.73% | 117.89% | -8.70% |
| Normalized Diluted EPS | 40.32% | -119.05% | 173.17% | 76.27% | -3.33% |
| Average Basic Shares Outstanding | 4.47% | 5.17% | 10.48% | 10.21% | 17.73% |
| Average Diluted Shares Outstanding | 4.47% | 5.17% | 10.48% | 10.21% | 17.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |